Pasithea Therapeutics (KTTA) Competitors $2.53 +0.05 (+2.02%) As of 03:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends KTTA vs. BGXX, AIM, HOTH, CRVO, RLMD, CLDI, TXMD, CSCI, ACXP, and APLMShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Bright Green (BGXX), AIM ImmunoTech (AIM), Hoth Therapeutics (HOTH), CervoMed (CRVO), Relmada Therapeutics (RLMD), Calidi Biotherapeutics (CLDI), TherapeuticsMD (TXMD), COSCIENS Biopharma (CSCI), Acurx Pharmaceuticals (ACXP), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Bright Green AIM ImmunoTech Hoth Therapeutics CervoMed Relmada Therapeutics Calidi Biotherapeutics TherapeuticsMD COSCIENS Biopharma Acurx Pharmaceuticals Apollomics Bright Green (NASDAQ:BGXX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Which has more volatility & risk, BGXX or KTTA? Bright Green has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Which has stronger valuation and earnings, BGXX or KTTA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright GreenN/AN/A-$13.13M-$0.06-1.48Pasithea TherapeuticsN/AN/A-$15.96MN/AN/A Does the media favor BGXX or KTTA? In the previous week, Pasithea Therapeutics had 1 more articles in the media than Bright Green. MarketBeat recorded 1 mentions for Pasithea Therapeutics and 0 mentions for Bright Green. Pasithea Therapeutics' average media sentiment score of 0.49 beat Bright Green's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Bright Green Neutral Pasithea Therapeutics Neutral Do institutionals & insiders believe in BGXX or KTTA? 7.8% of Bright Green shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 62.6% of Bright Green shares are owned by company insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor BGXX or KTTA? Pasithea Therapeutics received 2 more outperform votes than Bright Green when rated by MarketBeat users. CompanyUnderperformOutperformBright GreenN/AN/APasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% Is BGXX or KTTA more profitable? Pasithea Therapeutics' return on equity of -81.57% beat Bright Green's return on equity.Company Net Margins Return on Equity Return on Assets Bright GreenN/A -88.37% -55.30% Pasithea Therapeutics N/A -81.57%-74.31% SummaryPasithea Therapeutics beats Bright Green on 6 of the 9 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.21M$6.56B$5.39B$9.14BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A9.7988.1017.53Price / SalesN/A331.481,285.4080.11Price / CashN/A22.6336.6032.90Price / Book0.115.064.954.67Net Income-$15.96M$154.90M$117.96M$224.69M7 Day Performance-0.20%2.59%2.49%3.32%1 Month Performance-3.99%1.50%3.44%5.36%1 Year Performance-64.56%5.43%27.06%22.59% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics0.7961 of 5 stars$2.53+2.0%N/A-65.2%$3.21MN/A0.003BGXXBright GreenN/A$0.07+1.0%N/A-68.7%$13.19MN/A-1.152AIMAIM ImmunoTech1.8527 of 5 stars$0.20-4.7%$2.75+1,242.1%-49.1%$13.07M$190,000.00-0.4420HOTHHoth Therapeutics2.7033 of 5 stars$1.89-0.5%$4.00+111.6%+16.3%$13.05MN/A-1.434Gap DownCRVOCervoMed3.0831 of 5 stars$2.04-3.3%$42.00+1,958.8%-77.3%$12.59M$7.14M0.004News CoveragePositive NewsRLMDRelmada Therapeutics4.0718 of 5 stars$0.40-2.0%$4.25+952.0%-89.1%$12.19MN/A-0.1410CLDICalidi Biotherapeutics3.0694 of 5 stars$0.92+0.4%$16.67+1,714.0%N/A$12.02M$50,000.000.0038TXMDTherapeuticsMD0.616 of 5 stars$1.04-5.5%N/A-52.5%$11.99M$1.60M0.00420CSCICOSCIENS BiopharmaN/A$3.18-6.5%N/AN/A$11.95M$7.60M-0.2720Positive NewsACXPAcurx Pharmaceuticals3.033 of 5 stars$0.70-13.4%$12.00+1,614.3%-76.1%$11.83MN/A-0.643Short Interest ↓APLMApollomics2.3923 of 5 stars$10.85+2.9%$200.00+1,743.3%-89.3%$11.79M$1.22M0.0045 Related Companies and Tools Related Companies Bright Green Alternatives AIM ImmunoTech Alternatives Hoth Therapeutics Alternatives CervoMed Alternatives Relmada Therapeutics Alternatives Calidi Biotherapeutics Alternatives TherapeuticsMD Alternatives COSCIENS Biopharma Alternatives Acurx Pharmaceuticals Alternatives Apollomics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KTTA) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KTTA Stock Alerts